1 / 13

Chapter 28 Jonathan G. Howlett , John C. MacFadyen

Canadian Diabete s Association Clinical Practice Guidelines Treatment of Diabetes in People with Heart Failure. Chapter 28 Jonathan G. Howlett , John C. MacFadyen. Diabetes in Heart Failure Checklist. 2013.

meira
Télécharger la présentation

Chapter 28 Jonathan G. Howlett , John C. MacFadyen

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Canadian Diabetes Association Clinical Practice GuidelinesTreatment of Diabetes in People with Heart Failure Chapter 28 Jonathan G. Howlett, John C. MacFadyen

  2. Diabetes in Heart Failure Checklist 2013 • Treat heart failure in patients with diabetes the SAME as you would a patient without diabetes • METFORMIN recommended if eGFR >30 mL/min • If eGFR <60 mL/min, use RAAS blockade carefully • Do NOT use thiazolidinediones

  3. Diabetes → Increased Risk of Heart Failure Independent of Ischemia • Diabetic cardiomyopathy • 2 to 4-fold increase incidence of heart failure in DM • Asymptomatic abnormalities of ventricular systolic and diastolic function, independent of ischemic heart disease or systemic hypertension • Independent risk factors for CHF • Elevated A1C • Microalbuminuria

  4. Use the same heart failure therapies in diabetes as you would in non-diabetes based on the Canadian Cardiovascular Society (CCS) Recommendations (www.ccsguidelineprograms.ca)

  5. Use Same Treatments as in Non-diabetes … • Beta-blocker for systolic heart failure if indicated • Same target drug dose as indicated by CCS • If eGFR <60 mL/min • Starting dose of ACEi/ARB should be halved with gradual up-titration • Monitor electrolytes, creatinine, blood pressure, weight within 7-10 days of starting

  6. Metformin Use in Heart Failure Patients • Tayside, Scotland (population 400,000) • n=422 with CHF and diabetes • Antihyperglycemic therapy: • Metformin alone n=68 • SU alone n=217 • Combination n=137 1.0 0.8 0.4 Cumulative mortality Sulfonylurea monotherapy 0.6 Metformin monotherapy + combination 0 0.2 Time (days) ACEi= Angiotensin-Converting Enzyme inhibitor; CHF = Chronic Heart Failure; MI = Myocardial Infarction; SU = Sulfonylurea 3000 5000 2000 4000 1000 0 Evans JM, et al. Am J Cardiol 2010;106:1006-10.

  7. Metformin Use in Heart Failure Patients • Veterans Affairs • 6,185 with CHF & DM • Oral antihyperglycemic: • With metformin (n=1,561) • Without metformin • Statistically adjusted for co-variables 1.00 0.95 0.85 Metformin Survival estimates 0.90 No metformin 0.75 0.80 p = 0.01 Death: 0.76 (0.63-0.92) p < 0.01 CHF hospitalization: 0.93 (0.74-1.18) p = 0.56 Total hospitalization: 0.94 (0.83-1.07) p = 0.35 Time (days) 300 500 600 700 200 400 100 0 Aguilar D, et al. Circ Heart Fail 2011;4:53-8.

  8. Use metformin in heart failure patients when eGFR >30 mL/min

  9. Recommendation 1 • Individuals with diabetes and heart failure should receive the same heart failure therapies as those identified in the evidence- based Canadian Cardiovascular Society heart failure recommendations (http://www.ccsguidelineprograms.ca)[Grade D, Consensus]

  10. Recommendation 2 • In people with diabetes and heart failure and an eGFR <60 mL/min, or if combined RAAS blockade is employed: • Starting doses of ACE inhibitors or angiotensin receptor II antagonists (ARBs) should be halved[Grade D, Consensus]. • Serum electrolytes and creatinine, blood pressure and body weight, as well as heart failure symptoms and signs, should be monitored within 7-10 days of any initiation or titration of therapy [Grade D, Consensus]

  11. Recommendation 2 (continued) • Dose-up titration should be more gradual (with monitoring of blood pressure, serum potassium and creatinine) [Grade D, Consensus]. • The target drug doses should be the same as those identified in the evidence-based Canadian Cardiovascular Society recommendations on heart failure (http://www.ccsguidelineprograms.ca), if well tolerated[Grade D, Consensus]

  12. Recommendation 3 • Beta blockers should be prescribed when indicated for systolic heart failure, as they provide similar benefits in people with diabetes compared with people without diabetes[Grade B, Level 2]

  13. CDA Clinical Practice Guidelines www.guidelines.diabetes.ca – for professionals 1-800-BANTING (226-8464) www.diabetes.ca – for patients

More Related